Access! 2023 + IGBA 2023 Conference - Last chance to register, join us in Orlando, FL on Feb 13-16!

Drug Prices

Desi is Back Playing Soccer and Doing "Normal Kid" Stuff

When Desi's swollen ankle began hurting so much that he was unable to run and keep up with his friends, his parents, Jonathan and Susan of Maryland, became concerned. After several doctor visits, a rheumatologist diagnosed Desi with juvenile idiopathic arthritis (JIA), an autoimmune disease. To help manage the symptoms of JIA, Desi receives weekly injections of autoimmune suppressant medicine and daily doses of anti-inflammatory medicines.

Generics and Biosimilars Offer Savings for Patients Fighting Cancer, Heart Disease and Other Conditions

Generic and biosimilar medicines improve access and affordability for the millions of people with illnesses like asthma, arthritis, heart disease, and depression. While we now have effective treatment options to help patients manage their conditions, many brand drugs come with steep price tags. Fortunately, there are more affordable generic and biosimilar treatments that reduce costs for patients and increase access to lifesaving care.

Patients Pay More When Generic Drugs Are Placed On Non-Generic Tiers, Even Though Prices For Generics Are Going Down

Numerous studies agree: Generics provide savings on prescription drugs. And six years into a sustained period of price deflation, many generic prices are lower than ever. But inexplicably, patients are paying more for many generics. Although the Medicare program has rules to safeguard beneficiaries, it has allowed Medicare drug plans to make changes that require patients to pay more for many generic drugs even as the prices of those drugs have fallen.

How to Talk to Voters About the High Cost of Medicines and Ways to Lower Them

A Reference Guide for Lawmakers

With record high inflation, voters are concerned about the rising costs of goods – including life-saving medicines. AAM developed a resource for lawmakers to provide effective communications around the ever-increasing costs of medicines. This guide includes facts about generic and biosimilar medicines, the problems causing the high cost of medicine and solutions to lower drug prices for patients and their families.

Generics & Biosimilars Continue to Reward Patients, Employers and Taxpayers

At a time of rising health care costs, generic and biosimilar medicines continue to generate savings and increase access to care for patients. AAM’s 2022 U.S. Generic & Biosimilar Medicines Savings Report provides new insights across a variety of settings where savings reached greater heights, benefiting patients, consumers, employers, and taxpayers alike.

Here are five key takeaways from this year’s report:

October Can Now Afford to do More to Support Her Mental Health

In 2017, October felt her anxiety and panic attacks developing into something more serious: Her life, work, and relationships seemed meaningless. Realizing she needed help, October, age 26, sought in-hospital treatment in Maryland and was diagnosed with anxiety and chronic depression. She was started on a brand-name antidepressant; but after a change in health insurance coverage, she learned that her out-of-pocket costs for the medicine would be much higher. Her therapist recommended switching to a more affordable generic antidepressant, and she’s been on one ever since.

Generic and Biosimilar Drugs Generate A Record $373 Billion For America’s Patients and Healthcare System in 2021

Despite Savings from Generic Drugs, Many Patients Continue to Pay More than Necessary

WASHINGTON, DC (September 21, 2022) — Today, the Association for Accessible Medicines (AAM), the leading trade association for generic and biosimilar manufacturers, released its 2022 U.S. Generic & Biosimilar Medicines Savings Report highlighting the value of generic and biosimilar medicines.

AAM Statement: New Study Shows Formulary Abuses Force Patients to Pay More for Generic Drugs Even as the Prices of Those Drugs Go Down

WASHINGTON, D.C. (September 15, 2022) – The Association for Accessible Medicines (AAM) President and CEO Dan Leonard today released the following statement in response to new analysis by healthcare consulting firm, Avalere, showing that generic drugs continue to be misplaced on higher formulary tiers, unfairly driving up costs for patients:

Subscribe to Drug Prices

Association for Accessible Medicines


Sign-up for Updates

Receive relevant industry news, event information and the latest resources on biosimilars and generic medicines.

Stay Connected

For the latest updates, follow us on social media.